Literature DB >> 33832694

Non-IgE-mediated anaphylaxis.

Antonella Cianferoni1.   

Abstract

Anaphylaxis is a rapidly evolving, acute, life-threatening reaction that occurs rapidly on contact with a trigger. Anaphylaxis is classically defined as an allergen-driven process that induces specific IgE and the activation of mast cells and basophils through the cross-linking of IgE receptors. However, it is clear that non-IgE-mediated pathways can induce symptoms indistinguishable from those of classic anaphylaxis, and their activation could explain the severity of IgE-mediated anaphylaxis. Indeed, mast cells and basophils can be activated by antibodies against IgE or their receptors, by molecules such as anaphylatoxins, or through G-coupled receptors. Some other allergens can induce antibodies of class IgG that can activate neutrophils to produce a molecule similar to histamine to induce anaphylaxis. Finally, some inflammatory mediators such as bradykinin or prostaglandin can also modulate mast cell and basophil activation as well as directly cause vasodilation and bronchoconstriction, resulting in anaphylaxis-like reactions.
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; biologics; food allergy; mast cells

Year:  2021        PMID: 33832694     DOI: 10.1016/j.jaci.2021.02.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  Anaphylaxis knowledge gaps and future research priorities: A consensus report.

Authors:  Timothy E Dribin; David Schnadower; Julie Wang; Carlos A Camargo; Kenneth A Michelson; Marcus Shaker; Susan A Rudders; David Vyles; David B K Golden; Jonathan M Spergel; Ronna L Campbell; Mark I Neuman; Peter S Capucilli; Michael Pistiner; Mariana Castells; Juhee Lee; David C Brousseau; Lynda C Schneider; Amal H Assa'ad; Kimberly A Risma; Rakesh D Mistry; Dianne E Campbell; Margitta Worm; Paul J Turner; John K Witry; Yin Zhang; Brad Sobolewski; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2021-08-12       Impact factor: 10.793

2.  Novel MRGX2 Antagonists for Treating Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-06-21       Impact factor: 4.632

3.  Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice.

Authors:  Jyoti K Lama; Koji Iijima; Takao Kobayashi; Hirohito Kita
Journal:  J Allergy Clin Immunol       Date:  2022-01-29       Impact factor: 14.290

Review 4.  Anaphylaxis: Data Gaps and Research Needs.

Authors:  Timothy E Dribin; Mariana Castells
Journal:  Immunol Allergy Clin North Am       Date:  2022-02       Impact factor: 3.152

5.  What We Know about Sting-Related Deaths? Human Fatalities Caused by Hornet, Wasp and Bee Stings in Europe (1994-2016).

Authors:  Xesús Feás; Carmen Vidal; Susana Remesar
Journal:  Biology (Basel)       Date:  2022-02-11

Review 6.  Pathophysiological, Cellular, and Molecular Events of the Vascular System in Anaphylaxis.

Authors:  Emilio Nuñez-Borque; Sergio Fernandez-Bravo; Alma Yuste-Montalvo; Vanesa Esteban
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

Review 7.  Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing.

Authors:  Jason R Burchett; Jordan M Dailey; Sydney A Kee; Destiny T Pryor; Aditya Kotha; Roma A Kankaria; David B Straus; John J Ryan
Journal:  Cells       Date:  2022-09-27       Impact factor: 7.666

Review 8.  New Mechanistic Advances in FcεRI-Mast Cell-Mediated Allergic Signaling.

Authors:  Yang Li; Patrick S C Leung; M Eric Gershwin; Junmin Song
Journal:  Clin Rev Allergy Immunol       Date:  2022-10-17       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.